Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy

Aims: Diabetic cardiomyopathy (DCM) is an ill-defined entity. This study aims to explore the clinical characteristics and prognosis of diabetic patients that disparately develop heart failure (HF) with preserved ejection fraction (HFpEF) other than HF with reduced ejection fraction (HFrEF). Patients and Methods: A total of 911 patients diagnosed with diabetes mellitus were identified in the ChiHFpEF cohort (NCT05278026). DCM was defined as diabetic patients diagnosed with HF, absent from flow obstructive coronary artery disease (CAD), uncontrolled refractory hypertension and hemodynamics significant heart valvular diseases, arrhythmia and congenital heart diseases. The primary endpoint was a composite of all-cause death and rehospitalization due to HF. Results: As compared to DCM-HFrEF patients, DCM-HFpEF patients had a longer duration of diabetes, were older and more noticeable in hypertension and non-obstructive CAD. After a median follow-up of 45.5 months, survival analysis showed that DCM-HFpEF patients had a better composite endpoint. Cox regression implicated that non-obstructive CAD was a negative (HR 0.101, 95% CI 0.028–0.373, p = 0.001) predictor for the composite endpoint of DCM-HFrEF patients. Age was a positive predictor for the composite endpoint of DCM-HFpEF patients (HR 1.044, 95% CI 1.007–1.082, p = 0.018). Conclusion: DCM-HFpEF is a disparate entity from DCM-HFrEF. Additional phenomic studies are needed to explore the molecular mechanisms and develop targeted therapies.

[1]  Yue Gu,et al.  Involvement of pyroptosis pathway in epicardial adipose tissue - myocardium axis in experimental heart failure with preserved ejection fraction. , 2022, Biochemical and biophysical research communications.

[2]  Akshay S. Desai,et al.  Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.

[3]  K. Ejiri,et al.  Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus , 2022, International journal of molecular sciences.

[4]  F. Yiannikouris,et al.  The Role of (Pro)Renin Receptor in The Metabolic Syndrome. , 2022, Current hypertension reviews.

[5]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[6]  L. Ernande,et al.  The role of hyperglycaemia in the development of diabetic cardiomyopathy. , 2021, Archives of cardiovascular diseases.

[7]  J. Sowers,et al.  Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease , 2021, Hypertension.

[8]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[9]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[10]  M. Drazner Insights From the History and Physical Examination in HFpEF or HFrEF: Similarities and Differences. , 2021, JACC. Heart failure.

[11]  S. Pocock,et al.  Changes in Plasma Renin Activity after Renal Artery Sympathetic Denervation. , 2021, Journal of the American College of Cardiology.

[12]  N. Nair Epidemiology and pathogenesis of heart failure with preserved ejection fraction. , 2020, Reviews in cardiovascular medicine.

[13]  Shao-Liang Chen,et al.  Left atrial diameter and atrial fibrillation, but not elevated NT-proBNP, predict the development of pulmonary hypertension in patients with HFpEF , 2020, Journal of geriatric cardiology : JGC.

[14]  R. Gropler,et al.  Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy. , 2020, Circulation research.

[15]  B. Borlaug Evaluation and management of heart failure with preserved ejection fraction , 2020, Nature Reviews Cardiology.

[16]  Zhuyin Li,et al.  Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. , 2020, JACC. Heart failure.

[17]  R. Rodeheffer,et al.  Diabetes Mellitus Is an Independent Predictor for the Development of Heart Failure: A Population Study. , 2020, Mayo Clinic proceedings.

[18]  A. Rossi,et al.  Weight Loss and Hypertension in Obese Subjects , 2019, Nutrients.

[19]  I. Piña,et al.  Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.

[20]  Jingyan Dong,et al.  ALDH2 rs671 polymorphism and the risk of heart failure with preserved ejection fraction (HFpEF) in patients with cardiovascular diseases , 2019, Journal of Human Hypertension.

[21]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. , 2018, Diabetes research and clinical practice.

[22]  J. Sowers,et al.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.

[23]  Roland A Matsouaka,et al.  Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.

[24]  J. Sowers,et al.  Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease , 2017, Diabetologia.

[25]  Shaoliang Chen,et al.  Improvement of cardiac dysfunction by bilateral surgical renal denervation in animals with diabetes induced by high fructose and high fat diet. , 2016, Diabetes research and clinical practice.

[26]  Wing W. Chan,et al.  Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction. , 2015, The American journal of cardiology.

[27]  R. Ritchie,et al.  Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, Pharmacology & therapeutics.

[28]  R. Rodeheffer,et al.  The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. , 2014, Journal of cardiac failure.

[29]  E. Abel,et al.  Molecular mechanisms of diabetic cardiomyopathy , 2014, Diabetologia.

[30]  M. Cooper,et al.  Mechanisms of diabetic complications. , 2013, Physiological reviews.

[31]  B. Howard,et al.  Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study , 2010, Journal of hypertension.

[32]  T. Therneau,et al.  Hospitalizations after heart failure diagnosis a community perspective. , 2009, Journal of the American College of Cardiology.

[33]  P. Pozzoni,et al.  Heart Failure in Chronic Kidney Disease , 2005 .

[34]  Samy I McFarlane,et al.  Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. , 2003, The American journal of cardiology.

[35]  H. Krumholz,et al.  Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. , 2003, Journal of the American College of Cardiology.

[36]  J. Gardin,et al.  Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.

[37]  J. Osborn,et al.  LONG‐TERM INCREASES IN RENAL SYMPATHETIC NERVE ACTIVITY AND HYPERTENSION , 1997, Clinical and experimental pharmacology & physiology.

[38]  S. Oparil,et al.  Importance of the renal nerves in the pathogenesis of experimental hypertension. , 1982, Hypertension.

[39]  A. Grishman,et al.  New type of cardiomyopathy associated with diabetic glomerulosclerosis. , 1972, The American journal of cardiology.